182 related articles for article (PubMed ID: 26078574)
1. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis.
Sun J; Yuan YZ; Hou XH; Zou DW; Lu B; Chen MH; Liu F; Wu KC; Zou XP; Li YQ; Zhou LY
World J Gastroenterol; 2015 Jun; 21(22):6965-73. PubMed ID: 26078574
[TBL] [Abstract][Full Text] [Related]
2. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
5. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis.
Jin Y; Zhang S; Pan J; Yue M; Zhang G; Yao D; Wang Q
Pharmazie; 2019 Jul; 74(7):432-438. PubMed ID: 31288901
[TBL] [Abstract][Full Text] [Related]
6. On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study.
Cho JH; Koo JY; Kim KO; Lee SH; Jang BI; Kim TN
Medicine (Baltimore); 2018 Oct; 97(43):e12732. PubMed ID: 30412065
[TBL] [Abstract][Full Text] [Related]
7. The efficacy, safety and cost-effectiveness of hydrotalcite versus esomeprazole in on-demand therapy of NERD: A multicenter, randomized, open-label study in China.
Xiao YL; Nie YQ; Hou XH; Xie PY; Fang JY; Yuan YZ; Zhou LY; Zhao NQ; Chen MH
J Dig Dis; 2013 Sep; 14(9):463-8. PubMed ID: 23659834
[TBL] [Abstract][Full Text] [Related]
8. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
[TBL] [Abstract][Full Text] [Related]
9. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Fock KM; Teo EK; Ang TL; Chua TS; Ng TM; Tan YL
World J Gastroenterol; 2005 May; 11(20):3091-8. PubMed ID: 15918196
[TBL] [Abstract][Full Text] [Related]
10. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
11. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial.
Sun QH; Wang HY; Sun SD; Zhang X; Zhang H
World J Gastroenterol; 2019 May; 25(17):2110-2121. PubMed ID: 31114137
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of esomeprazole for treatment of poorly controlled asthma.
; Mastronarde JG; Anthonisen NR; Castro M; Holbrook JT; Leone FT; Teague WG; Wise RA
N Engl J Med; 2009 Apr; 360(15):1487-99. PubMed ID: 19357404
[TBL] [Abstract][Full Text] [Related]
14. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
Gillessen A; Beil W; Modlin IM; Gatz G; Hole U
J Clin Gastroenterol; 2004 Apr; 38(4):332-40. PubMed ID: 15087692
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
Talley NJ; Lauritsen K; Tunturi-Hihnala H; Lind T; Moum B; Bang C; Schulz T; Omland TM; Delle M; Junghard O
Aliment Pharmacol Ther; 2001 Mar; 15(3):347-54. PubMed ID: 11207509
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
[TBL] [Abstract][Full Text] [Related]
18. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.
Tan VP; Wong WM; Cheung TK; Lai KC; Hung IF; Chan P; Pang R; Wong BC
J Gastroenterol; 2011 Jul; 46(7):906-12. PubMed ID: 21538030
[TBL] [Abstract][Full Text] [Related]
19. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms.
Scholten T; Gatz G; Hole U
Aliment Pharmacol Ther; 2003 Sep; 18(6):587-94. PubMed ID: 12969085
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
Szucs T; Thalmann C; Michetti P; Beglinger C
Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
